NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) announced that clinical data on rusfertide in polycythemia vera, including the ...

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced ...

Copyright 2026 The Associated Press. All Rights Reserved. Copyright 2026 The Associated Press. All Rights Reserved. Artists Olimpia Zagnoli, left, and Carolina ...

SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on the transformative ...

To support global participation, all posters will be available on-demand throughout the 2025 APS Global Psychological Science Summit event days, October 21-23, 2025. Poster presentations are not ...

ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection ...

Title: Phase 1/2 Duravelo-1 study: Preliminary results of Nectin-4-targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally ...

The inter-university business case competition 'TexBiz 2025,' organised by the BUTEX Business Club, has taken on a new dimension this year. The signature case competition now features two captivating ...

Over the summer and fall of 2024, ICAP supported 18 students from Columbia Mailman School of Public Health and the Fu Foundation School of Engineering and Applied Sciences in completing their required ...